GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has closed a $26 million Series A financing.

No Comments

Sorry, the comment form is closed at this time.